Relative Bioavailability of Four Alternative Oral Formulations Versus the Current Tablet Formulation of Lapatinib.

Trial Profile

Relative Bioavailability of Four Alternative Oral Formulations Versus the Current Tablet Formulation of Lapatinib.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 19 Feb 2015

At a glance

  • Drugs Lapatinib (Primary)
  • Indications Cancer
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 15 Feb 2015 Status changed from suspended to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
    • 12 Oct 2008 Status changed from discontinued to suspended as reported by ClinicalTrials.gov.
    • 02 Sep 2008 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top